Señales en vivo de ANP.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 ene 2024 @ 23:56):

Stats
Volumen de hoy	869 280
Volumen promedio	548 968
Capitalización de mercado	52.29M
EPS	$0 ( 2024-02-19 )
Próxima fecha de ganancias	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.90
ATR14	$0.00300 (5.36%)

Volumen Correlación

Largo: -0.22 (neutral)

Corto: -0.74 (moderate negative)

Signal:(44.832) Neutral

Antisense Therapeutics Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Antisense Therapeutics Correlación - Moneda/Commodity

-0.68
( moderate negative )

-0.56
( weak negative )

0.00
( neutral )

0.47
( neutral )

Antisense Therapeutics Finanzas

Annual	2022
Ingresos:	$1.58M
Beneficio Bruto:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
Ingresos:	$1.58M
Beneficio Bruto:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.00920

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0209

Financial Reports:

No articles found.

Antisense Therapeutics

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.